Press Release Details

View all news

ADC Therapeutics Presented Positive Pre-clinical Activity of its Novel Anti-CD22 Antibody-Drug Conjugate at the American Association for Cancer Research (AACR) Annual Meeting

April, 19, 2015

19 April 2015

Lausanne, Switzerland and London, UK, April 19 2015 – ADC Therapeutics (ADCT) today presented the following abstract: “Pre-clinical Activity of hLL2-PBD, a Novel Anti-CD22 Antibody-Pyrrolobenzodiazepine (PBD) Conjugate in Models of Non-Hodgkin Lymphoma” at the 2015 American Association for Cancer Research (AACR) Annual Meeting, Philadelphia, Pennsylvania, USA.

Highlights of the data presented include:

  • Potent and specific in vitro and in vivo anti-tumor activity of hLL2-PBD against CD22-positive hematological tumors
  • Remarkably superior in vivo anti-tumor efficacy compared to the Genentech anti-CD22 ADC Hu10F4-vcMMAE
  • Favorable pharmacokinetic (PK) profile of hLL2-PBD in mice.

Commenting on the results, Dr Patrick van Berkel, Senior Vice President Research & Development at ADC Therapeutics said “The fact that our ADC showed superior in vivo anti-tumour efficacy to Hu10F4-vcMMAE is highly encouraging. PBD dimers represent a novel class of toxin, which bind DNA in the minor groove and form highly cytotoxic interstrand cross-links, offering the potential to not only enhance the efficacy of ADCs, but also to reduce resistance to ADCs with different payloads.”

The study was conducted jointly by ADC Therapeutics, Spirogen (a division of AstraZeneca) and University College London, London.

Download the PDF of the Pre-clinical Activity of hLL2-PBD poster.

Notes to Editors

About ADC Therapeutics (

ADC Therapeutics Sàrl (ADCT) is an oncology drug development company that specializes in the development of proprietary Antibody Drug Conjugates (ADCs) targeting major solid and hematological cancers. The Company’s ADCs are highly targeted drug constructs which combine monoclonal antibodies specific to surface antigens on particular tumor cells with a novel class of highly potent pyrrolobenzodiazepine (PBD)-based warheads. The Company has access to warhead and linkers chemistries via agreements with Spirogen (a wholly-owned subsidiary of AstraZeneca’s MedImmune). It is progressing eleven ADC programs, two of these under a joint development agreement with MedImmune.

ADCT was established in 2012 by private equity firm Auven Therapeutics. In 2013, AstraZeneca acquired an equity stake in the Company and entered into a corporate partnership for two ADC programs. The Company has more than $100 million in committed capital to develop its pipeline of proprietary antibody drug conjugates. It is located in Lausanne, Switzerland, and utilizes laboratory facilities at Queen Mary Bioenterprises Innovation Centre, London, UK.

For more information please contact:

Media enquiries:
Instinctif Partners Sue Charles/ Gemma Howe
T: +44 (0)20 7866 7866

Multimedia Files:

Categories: Press Releases
View all news